IRLAB Therapeutics AB (publ)
SSE:IRLAB-A.ST
14.45 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | IRLAB Therapeutics AB (publ) |
Symbool | IRLAB-A.ST |
Munteenheid | SEK |
Prijs | 14.45 |
Beurswaarde | 748,345,270 |
Dividendpercentage | 0% |
52-weken bereik | 5.58 - 18 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Gunnar Olsson |
Website | https://www.irlab.se |
An error occurred while fetching data.
Over IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)